Neurocrine Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBIX research report →
Range $165 – $225
Price Chart
About the company
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages.
- CEO
- Kyle W. Gano
- IPO
- 1996
- Employees
- 2,500
- HQ
- San Diego, CA, US
AI snapshot
Six angles, distilled from the data.
NBIX remains in a constructive multi-month uptrend, trading above both the 50-day and 200-day moving averages. The stock is still well below its 52-week high of 186.12, but far from the 52-week low of 122.14, keeping the setup in the upper half of its yearly range.
Street sentiment stays constructive: 32 Buy ratings, 5 Hold, and no Sell ratings, with a 203.41 consensus target versus a 165.24 share price. Recent changes have leaned positive, including Guggenheim lifting its target to 224 and Cantor reiterating Overweight, while Bernstein kept Outperform unchanged.
The earnings backdrop is favorable after three straight EPS beats, including a 42.6% surprise in the latest quarter. Next-year EPS is modeled at 12.299 versus 6.66 TTM, so shareholders should watch whether revenue growth and margin discipline keep supporting that step-up.
The pattern is net selling, but most of the activity is non-discretionary award and exempt-share movement rather than clean open-market conviction. The only clear discretionary signal is director George Morrow’s repeated sales; the chief medical officer’s activity was award-related, which is not a bearish read by itself.
Profitability is solid, with a 64.7% gross margin, 26.6% operating margin, and 19.0% net margin. Growth is still strong at 41.2% revenue growth year over year, while the balance sheet remains net cash positive by $1.065 billion with $816.7 million in free cash flow in 2025.
NBIX screens as a premium biotech name with stronger profitability than many specialty pharma peers, supported by high margins and positive cash generation. The valuation still looks rich relative to the sector, with a 23.88 P/E and a target range that implies further upside if execution holds.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $15.24B
- P/E
- 23.80
- Fwd P/E
- 20.53
- PEG
- 0.39
- P/S
- 4.54
- P/B
- 4.35
- EV/EBITDA
- 17.48
- Div Yield
- 0.00%
- Gross Margin
- 97.81%
- Op Margin
- 23.81%
- Net Margin
- 18.98%
- ROE
- 19.74%
- ROIC
- 14.30%
Latest fiscal year · YoY change
- Revenue
- $2.86B+21.4%
- Gross Profit
- $2.81B+21.0%
- Op Income
- $619.10M
- Net Income
- $478.60M+40.2%
- EPS
- $4.81+41.5%
- OCF Growth
- +31.5%
- FCF Growth
- +34.4%
- 52W High
- $186.12
- 52W Low
- $122.14
- 50D MA
- $149.14
- 200D MA
- $149.38
- Beta
- 0.33
- RSI (14)
- 43
- Avg Volume
- 1.33M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Neurocrine posted record third-quarter sales and profitability, raised INGREZZA guidance again, and signaled confidence in a diversified growth story heading into a catalyst-heavy 2027.· November 2, 2026
- Record net product sales exceeded $1.1 billion, with record profitability and non-GAAP EPS above $3 per share.
- INGREZZA sales were $801 million, up 17% year over year, and full-year guidance was raised to $2.9 billion-$2.925 billion.
- CRENESSITY reached $211 million in quarterly sales and VYKAT XR crossed $100 million for the first time at $107 million.
- Management said 2027 should bring continued double-digit INGREZZA volume growth, strong access, and mid- to high single-digit price concessions that should be offset by volume.
- The pipeline remains active, with Phase III readouts for osavampator and direclidine expected in 2027 and several new studies already started.
Third-quarter net product sales were a record more than $1.1 billion, up more than 40% year over year, and non-GAAP earnings were above $3 per share. INGREZZA sales were $801 million, up 17% year over year; CRENESSITY sales were $211 million; and VYKAT XR sales were $107 million. Management said INGREZZA included a $20 million benefit from customer order timing that is expected to reverse in Q4, and it raised full-year INGREZZA guidance to $2.9 billion-$2.925 billion. The company ended the quarter with approximately $800 million in cash, generated $400 million in operating cash flow, and used about $100 million for share repurchases and dilution offset. Looking ahead, management expects INGREZZA to continue double-digit volume growth in 2027, with mid- to high single-digit net pricing headwinds more than offset by volume; formal 2027 sales guidance will come in February.
Kyle Gano framed the quarter as proof that Neurocrine is becoming a diversified, highly profitable biopharma company, emphasizing record sales, record profitability, and strength across three commercial products. He said the company is approaching a potentially transformative period, with important clinical milestones in 2027 and an R&D Day in December that will include a VYKAT XR update and pipeline discussion. His tone was confident and upbeat, with repeated emphasis on long-term growth, disciplined execution, and shareholder value.
Matt Abernethy highlighted that the company delivered record revenue, more than 40% year-over-year growth, and non-GAAP EPS above $3, reflecting operating leverage while still investing in commercial growth and R&D. He said INGREZZA’s underlying performance exceeded internal expectations, prompting another raise in full-year guidance to $2.9 billion-$2.925 billion, and noted the $20 million timing benefit in Q3 that should reverse in Q4. He also pointed to approximately $800 million in cash, $400 million in operating cash flow, and about $100 million used for share repurchases and dilution offset, while reiterating capital allocation priorities of commercial growth, pipeline advancement, and disciplined business development.
Analysts focused heavily on INGREZZA’s Q4 trajectory, 2027 pricing and access, and whether the Q3 beat was flattered by timing; management said Q4 should still see mid-teen underlying TRx growth, with normal seasonality in gross-to-net. VYKAT XR drew several questions about safety reports, discontinuations, and growth durability; management said growth could be delayed by recent external events but reiterated confidence in the benefit-risk profile, said net adds were positive in Q3, and stressed close post-marketing monitoring. On the pipeline, management defended direclidine’s schizophrenia opportunity, said the Phase III program is on track, and noted low discontinuation rates in the current study; they also explained that the discontinued M4 antagonist 986 was dropped for lack of sufficient data, not safety issues.
The company has three growing commercial products, with INGREZZA still compounding nine years after launch, CRENESSITY showing steady adoption, and VYKAT XR now contributing meaningful revenue. Management sounded confident that 2027 can be another growth year, supported by strong access for INGREZZA, continued commercial expansion, and a broad pipeline with multiple Phase II/III milestones ahead.
VYKAT XR faces the clearest near-term uncertainty: management acknowledged external safety-related headlines, said launch growth may be delayed, and admitted the business is still being understood in the real world. INGREZZA also faces 2027 pricing pressure, with management citing mid- to high single-digit price concessions, and the company remains dependent on continued execution in launches and pipeline programs to sustain momentum.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.8%
- Shares Outstanding
- 101.22M
- Float Shares
- 100.00M
of shares held by institutions
802 13F filers
Buy/sell ratio 0.35. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NBIX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa C. McClainHouse · MI09 | Sell | Jun 17, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 11, 25 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Nov 19, 24 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Aug 26, 24 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Oct 27, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Oct 27, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Aug 14, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Aug 14, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | May 2, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | May 2, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Feb 10, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Dec 16, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Dec 16, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Dec 6, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 14.86M | ▲ 1.14M |
| Vanguard Group Inc | 9.70M | ▼ 6.26K |
| Dodge & Cox | 5.50M | ▼ 80.13K |
| Jpmorgan Chase & Co | 5.29M | ▼ 1.11M |
| Vanguard Portfolio Management LLC | 5.06M | ▲ 85.95K |
| State Street Corp | 4.81M | ▲ 422.38K |
| Vanguard Capital Management LLC | 4.58M | ▲ 35.46K |
| Aqr Capital Management LLC | 3.82M | ▼ 1.12M |
| Renaissance Technologies LLC | 2.30M | ▼ 35.20K |
| Geode Capital Management, LLC | 2.13M | ▼ 11.29K |
| Two Sigma Investments, LP | 2.08M | ▼ 984.31K |
| Vestal Point Capital, LP | 1.88M | ▲ 630.00K |
Held by 1,357 ETFs
Biggest fund positions in NBIX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | LYONS GARY A | other | 15,000 |
| Nov 17, 26 | LYONS GARY A | sell | 1,200 |
| Nov 17, 26 | LYONS GARY A | sell | 4,011 |
| Nov 17, 26 | LYONS GARY A | sell | 5,689 |
| Nov 17, 26 | LYONS GARY A | sell | 4,100 |
| Nov 17, 26 | LYONS GARY A | other | 15,000 |
| Nov 4, 26 | ROBERTS EIRY | other | 8,314 |
| Nov 4, 26 | ROBERTS EIRY | other | 1,506 |
| Nov 2, 26 | MORROW GEORGE J | other | 7,500 |
| Nov 3, 26 | MORROW GEORGE J | other | 7,200 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NBIX coverage
Recent articles, reports, and earnings notes.

Neurocrine Biosciences (NBIX): Growth Franchise With Pipeline Upside
Neurocrine Biosciences pairs a profitable commercial base with accelerating sales from INGREZZA, CRENESSITY, and newly acquired VYKAT XR. The stock screens as a Buy on strong revenue growth, solid cash generation, and a broad late-stage pipeline.

Neurocrine Biosciences, Inc. (NBIX) climbs 10% after hours
Neurocrine Biosciences, Inc. (NBIX) climbs after hours as traders position for its Q3 2026 earnings event. Strong first-half sales growth, led by INGREZZA, CRENESSITY, and VYKAT XR, supports the move, though competition and product safety concerns remain key risks for investors.

Latigo Biotherapeutics IPO: The Bull and Bear Case
Latigo Biotherapeutics, Inc. (NASDAQ: LTGO) is expected to list on 2026-08-07 at a price range of $16.00 to $18.00 per share. The company is offering 16,000,000 shares, with a disclosed market cap of $331.2 million. The bull case is a differentiated non-opioid pain platform; the bear case is a clinical-stage biotech with no revenue, rising losses, and a long road to approval.
Want a deeper read on NBIX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Neurocrine Biosciences (NBIX) is a Top-Ranked Momentum Stock: Should You Buy?
zacks.com · Nov 20
Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term
zacks.com · Nov 16
Eurizon Capital SGR S.p.A. Sells 10,154 Shares of Neurocrine Biosciences, Inc. $NBIX
defenseworld.net · Nov 16
NBIX or GRDN: Which Is the Better Value Stock Right Now?
zacks.com · Nov 10
Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
prnewswire.com · Nov 10
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
zacks.com · Nov 9
All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy
zacks.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 17, 2026 · Live quote · Not investment advice